Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR7 | Q9NYK1 | 18/20 | 0.50 |
| ▸ | TLR8 | Q9NR97 | 6/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | HRH2 | P25021 | 1/20 | 0.49 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.49 |
| ▸ | HTR2A | P28223 | 1/20 | 0.49 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.49 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.49 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.49 |
| ▸ | HTR2B | P41595 | 1/20 | 0.49 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.49 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4555124 | 0.94 | TLR7 (0.48) | TLR7TLR8LMNAPOLBHRH2 | |
| SCHEMBL146930 | 0.91 | TLR7 (0.58) | TLR7TLR8LMNAPOLBHRH2 | |
| SCHEMBL30447361 | 0.91 | TLR7 (0.58) | TLR7TLR8LMNAPOLBHRH2 | |
| SCHEMBL144157 | 0.91 | TLR7 (0.58) | TLR7TLR8LMNAPOLBHRH2 | |
| SCHEMBL5139195 | 0.90 | TLR7 (0.44) | TLR7TLR8LMNAPOLBHRH2 | |
| SCHEMBL4620764 | 0.83 | TLR7 (0.34) | TLR7TLR8LMNAPOLBHRH2 | |
| SCHEMBL4238527 | 0.82 | TLR7 (0.45) | TLR7TLR8LMNAPOLBHRH2 | |
| SCHEMBL148087 | 0.81 | TLR7 (0.57) | TLR7TLR8LMNAPOLBHRH2 | |
| SCHEMBL4015090 | 0.81 | TLR7 (0.50) | TLR7TLR8LMNAPOLBHRH2 | |
| SCHEMBL152034 | 0.81 | TLR7 (0.54) | TLR7TLR8LMNAPOLBHRH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11813323-B2 | RSV immunization regimen | GLAXOSMITHKLINE BIOLOGICALS SA (BE) | 2023-11-14 | — | — | US | disclosed |
| US-20230357369-A1 | RSV F PROTEIN COMPOSITIONS AND METHODS FOR MAKING SAME | GLAXOSMITHKLINE BIOLOGICALS SA (BE) | 2023-11-09 | — | — | US | disclosed |
| EP-4218800-A1 | RSV F PROTEIN COMPOSITIONS AND METHODS FOR MAKING SAME | GlaxoSmithKline Biologicals S.A. (BE) | 2023-08-02 | — | — | EP | disclosed |
| EP-4183412-A1 | RSV F PROTEIN COMPOSITIONS AND METHODS FOR MAKING SAME | GlaxoSmithKline Biologicals S.A. (BE) | 2023-05-24 | — | — | EP | disclosed |
| US-20230072995-A1 | RSV IMMUNIZATION REGIMEN | GLAXOSMITHKLINE BIOLOGICALS SA (BE) | 2023-03-09 | — | — | US | disclosed |
| EP-3178490-B1 | RSV F PROTEIN COMPOSITIONS AND METHODS FOR MAKING SAME | GLAXOSMITHKLINE BIOLOGICALS SA (BE) | 2022-04-20 | — | — | EP | disclosed |
| EP-3527224-A1 | RSV IMMUNIZATION REGIMEN | GlaxoSmithKline Biologicals S.A. (BE) | 2019-08-21 | — | — | EP | disclosed |
| EP-2667892-B1 | RSV IMMUNIZATION REGIMEN | GLAXOSMITHKLINE BIOLOGICALS SA (BE) | 2019-03-27 | — | — | EP | disclosed |
| EP-2192918-A1 | HIV ENV PROTEINS WITH MODIFICATIONS IN THE V3 LOOP | Novartis Ag (CH) | 2010-06-09 | — | — | EP | disclosed |
| WO-2009029569-A1 | HIV ENV PROTEINS WITH MODIFICATIONS IN THE V3 LOOP | NOVARTIS VACCINES AND DIAGNOSTICS INC. (US) | 2009-03-05 | — | — | WO | disclosed |
| EP-1976559-A2 | INFLUENZA VACCINES CONTAINING HEMAGGLUTININ AND MATRIX PROTEINS | Novartis Vaccines and Diagnostics GmbH & Co. KG (DE) | 2008-10-08 | — | — | EP | disclosed |
| WO-2007085969-A2 | INFLUENZA VACCINES CONTAINING HEMAGGLUTININ AND MATRIX PROTEINS | NOVARTIS VACCINES AND DIAGNOSTICS GMBH & CO KG (DE) | 2007-08-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11813323-B2 | RSV immunization regimen | IL5, IL15, IFNG | TLR7 48/4885TLR8 77/4885LMNA 4368/4885 |
| US-20230357369-A1 | RSV F PROTEIN COMPOSITIONS AND METHODS FOR MAKING SAME | RNASEL, TIMCC, RNGTT | TLR7 349/4885TLR8 1489/4885LMNA 2071/4885 |
| US-20230072995-A1 | RSV IMMUNIZATION REGIMEN | IL5, IL15, IFNG | TLR7 48/4885TLR8 77/4885LMNA 4368/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.